R&D Tax Credits for Medical Device and Biotech Companies

Key Takeaways

• Life sciences R&D credits can equal up to 25% of qualified spending when combining federal and state incentives — one of the highest-yield industries for R&D studies
• FDA design controls documentation (design history files, V&V protocols, engineering change orders) can serve as R&D credit substantiation — but only if it demonstrates experimentation, not just compliance
• The Orphan Drug Credit under IRC §45C provides a separate 25% credit on qualified clinical testing expenses for FDA-designated orphan drugs — on top of the standard §41 R&D credit
• Pre-revenue biotech startups can apply up to $500,000/year of R&D credits against payroll taxes under the QSB payroll tax offset — critical runway extension for companies years from first revenue

Activity Category	Specific Examples
Drug and biologic development	Novel compound synthesis, high-throughput screening, lead optimization, formulation development, drug delivery system engineering, bioequivalence studies, pharmacokinetic modeling, stability testing.
Medical device design and engineering	Device concept development, mechanical and electrical engineering, biocompatibility testing, materials selection and evaluation, software development for embedded systems, human factors engineering, usability testing.
Clinical trials (Phases I-III)	Protocol design, site selection engineering, dosage optimization, safety and efficacy evaluation, biostatistical analysis, adverse event investigation, pharmacovigilance systems development. Costs incurred before FDA marketing approval generally qualify.
Verification and validation (V&V)	Design verification testing, design validation testing, process validation, software validation, environmental testing (biocompatibility, sterilization, shelf life), EMC/EMI testing, performance testing against design inputs.
Manufacturing process development	Developing new manufacturing processes for medical devices or biologics. Scale-up from bench to production. Sterilization process development and validation. Cleanroom process engineering. Yield and consistency improvement.
Diagnostic and assay development	Developing new diagnostic tests, in vitro diagnostic (IVD) platforms, point-of-care testing devices, biomarker assays, companion diagnostics, sensitivity/specificity optimization.
Software as a Medical Device (SaMD)	AI/ML algorithm development for clinical decision support, patient monitoring software, medical imaging analysis, telehealth platform development, EHR integration engineering, cybersecurity for connected devices.

Quotable fact: Your research doesn’t need to succeed to qualify for the R&D credit. In an industry where iteration and redesign are standard practice — and where most drug candidates fail before reaching market — the credit rewards the process of experimentation itself. Failed products, abandoned formulations, and discontinued device programs all qualify if the four-part test was met when the work took place.

💡
From our practice: The IRS will not accept FDA regulatory documentation as automatic proof of R&D credit eligibility. A design history file shows your quality system compliance — but an examiner will ask whether the documented activities actually involved technical uncertainty and experimentation. The strongest approach maps each design control phase to the four-part test explicitly. What was the uncertainty? What alternatives did the team evaluate? How did they resolve it? Companies that layer this R&D credit analysis onto their existing quality system documentation build the strongest audit positions we’ve seen.

Orphan Drug Credit — IRC §45C

25% of qualified clinical testing expenses

This credit covers wages, supplies, and contract research costs for human clinical testing. The testing must occur after the date of FDA orphan drug designation and before marketing approval.

Stacks with the §41 R&D credit

The orphan drug credit and the standard R&D credit can be claimed on different categories of expenses for the same drug. Non-clinical research (preclinical, formulation, manufacturing) goes to §41. Clinical testing goes to §45C. They’re complementary.

No double-dipping on the same expenses

You can’t claim the same expenses under both credits. The optimal strategy allocates clinical testing costs to §45C (25% rate) and non-clinical R&D costs to §41. This maximizes the combined benefit across both provisions.

Why this matters for biotech: A company that incorporated in 2018 but didn’t generate its first revenue until 2024 can still qualify as a QSB. The test looks at when gross receipts first appeared, not when the company was founded. A biotech company with $0 revenue in its early years and under $5M in current-year revenue can apply up to $500,000/year in R&D credits against payroll taxes — even with zero income tax liability. Over the 5-year eligibility window, that’s up to $2.5M in cash flow. For many startups, this is the difference between reaching the next funding round and running out of runway.

Activities that don’t qualify:

✕	Routine production and quality control — manufacturing to established specs, incoming inspection to documented procedures, routine batch release testing
✕	Regulatory submission preparation — writing 510(k) or PMA applications, preparing regulatory filings, compiling documentation packages for submission (the engineering behind the data qualifies; the paperwork doesn’t)
✕	Phase IV / post-market studies — studies conducted after FDA marketing approval generally don’t qualify for the standard R&D credit (the technical uncertainty has been resolved by approval)
✕	Technology transfer with no experimentation — transferring an established process or product to a new manufacturing site without new technical challenges
✕	Foreign research — clinical trials, lab work, or development performed outside the U.S. is excluded from the federal credit under IRC §41(d)(4)(F)

💡
The Phase IV nuance: While Phase IV (post-market) studies generally don’t qualify for the standard R&D credit, there are exceptions. If a company is conducting Phase IV studies to support a new indication, a label expansion, or a new patient population — and those studies involve genuine technical uncertainty about safety or efficacy in the new context — the activities may qualify. The key question is whether the study is resolving new uncertainty or simply monitoring a known product. This distinction requires case-by-case analysis.

Life Sciences Company? Let’s Quantify Your R&D Credits.

We’ll map your development activities to the four-part test, evaluate CRO and grant-funded expenses, analyze orphan drug credit eligibility if applicable, and estimate your combined federal and state credit value.

Schedule a Free Consultation

Do clinical trials qualify for the R&D credit?

Generally yes. Phases I through III clinical trials conducted before FDA marketing approval involve resolving technical uncertainty about dosage, safety, and efficacy through systematic experimentation. You can claim the costs of protocol design, patient enrollment engineering, data analysis, and adverse event investigation. Phase IV studies generally don’t qualify unless they address new indications or patient populations with genuine technical uncertainty.

Can we claim credits on CRO expenses?

Yes — you can claim 65% of payments to U.S.-based CROs performing qualified research on your behalf as contract research QREs. You must retain substantial rights to the resulting IP and bear the financial risk. Structure your CRO arrangements to avoid the funded research exclusion — the company funding the CRO claims the credit, not the CRO itself.

What about FDA 510(k) work — does that qualify?

The engineering and testing behind a 510(k) submission can qualify. Think design verification, performance testing, biocompatibility evaluation, and software validation. However, the submission preparation itself doesn’t qualify — writing the application and compiling the regulatory package are compliance activities. The key distinction: the experimental work that generates the data qualifies; the regulatory paperwork that organizes it does not.

We’re pre-revenue — can we still benefit?

Absolutely. The QSB payroll tax offset allows companies with under $5M in gross receipts to apply up to $500,000/year of R&D credits against payroll taxes. Biotech companies that operated for years before generating revenue can qualify even if they’re more than 5 years old — the test measures when gross receipts first appeared, not when the company was founded. Combined with Section 174A immediate expensing, pre-revenue biotech companies have more tax tools available now than at any point in recent history.

How much is the R&D credit typically worth for a medical device or biotech company?

Life sciences companies can see combined federal and state credits equaling up to 25% of qualified spending, making this one of the highest-yield industries for R&D studies. A mid-size medical device company with $5M in qualifying R&D expenses might generate $300,000-$500,000 in annual federal credits, plus applicable state credits. For companies with orphan drug designations, the combined benefit of §41 + §45C can be even higher. Read our complete R&D tax credit guide for calculation methodology.